Nancy Hong
Director/Miembro de la Junta en Sequre Dx, Inc. .
Perfil
Nancy A.
Hong is the founder of Phenomix Corp.
founded in 2002.
Currently, she holds multiple positions including Managing Director at RiverVest Venture Management LLC, Director at Xilio Therapeutics LLC, and Board Member at Biolinq, Inc., Scout Bio, Inc., Sequre Dx, Inc., and Bluejay Therapeutics, Inc. She previously worked as a Senior Analyst at Forward Ventures Services LLC, Principal at Novartis Institute for Functional Genomics, Inc., Senior Associate at BioMed Ventures, and President at Archmont Biopharma, Inc. She also served as a Director at Xilio Therapeutics, Inc. Dr. Hong received her undergraduate degree from California Institute of Technology and her doctorate from the University of California, Berkeley.
Cargos activos de Nancy Hong
Empresas | Cargo | Inicio |
---|---|---|
RiverVest Venture Management LLC
RiverVest Venture Management LLC Investment ManagersFinance RiverVest Venture Management LLC (RiverVest Venture Partners) is a venture capital firm founded in 2000 by Thomas Melzer, Craig Andrew and Jay Schmelter. The firm is headquartered in St. Louis, Missouri. | Inversor de Capital Privado | 01/04/2016 |
Sequre Dx, Inc.
Sequre Dx, Inc. Medical/Nursing ServicesHealth Services Sequre Dx, Inc. is a genomics intelligence company that focuses on advancing on-target gene editing and cell therapies from discovery to patient. The company is based in Waltham, MA. The company offers preclinical platforms for the biopharma industry, including diagnostic assays and bioinformatic analytics that solve preclinical off-target evaluation needs. Sequre Dx aims to make gene editing and cell therapies suitable for all patients who would benefit from these life-saving technologies. The CEO of the company is Ellen E. Sheets. | Director/Miembro de la Junta | 01/04/2021 |
Biolinq, Inc.
Biolinq, Inc. Electronic Production EquipmentElectronic Technology Biolinq, Inc. develops skin-applied electronic sensors that analyze body fluids to provide health information. The company was founded by Jared Tangney and Josh Windmiller in 2012 and is headquartered in San Diego, CA. | Director/Miembro de la Junta | 01/09/2021 |
Xilio Therapeutics LLC
Xilio Therapeutics LLC Pharmaceuticals: MajorHealth Technology Part of Xilio Therapeutics, Inc., Xilio Therapeutics LLC develops cancer biopharmaceuticals. The company is based in Waltham, MA. The CEO of the company is René Russo. | Director/Miembro de la Junta | 02/03/2020 |
Bluejay Therapeutics, Inc.
Bluejay Therapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services Bluejay Therapeutics, Inc. is a clinical stage private biopharmaceutical company that is committed to developing effective treatments and cures for viral and liver diseases. The company is based in San Mateo, CA, and was founded by Keting Chu, who has been the CEO since incorporation. The company's first target indication is chronic hepatitis b, which is a worldwide prevalent disease with an urgent unmet medical need. Bluejay is advancing two innovative approaches with the potential for a high rate of functional cure: fully human igg1 anti-hbs monoclonal antibodies and first-in-class hbsag oral small molecule inhibitors. The company believes that by reducing hepatitis b surface antigen and restoring adaptive immunity, a functional cure could be achieved for patients. | Director/Miembro de la Junta | 01/06/2021 |
Scout Bio, Inc.
Scout Bio, Inc. Pharmaceuticals: MajorHealth Technology Scout Bio, Inc. operates as a biotechnology company that focuses on the innovation of pet medicine by delivering a pipeline of one-time therapeutics for major chronic pet health conditions. It also specializes in gene therapy, veterinary product development and biotechnology investment. The company was founded by James M. Wilson in 2016 and is headquartered in Philadelphia, PA. | Director/Miembro de la Junta | 01/04/2019 |
Antiguos cargos conocidos de Nancy Hong.
Empresas | Cargo | Fin |
---|---|---|
Novartis Institute for Functional Genomics, Inc.
Novartis Institute for Functional Genomics, Inc. Miscellaneous Commercial ServicesCommercial Services Novartis Institute For Functional Genomics, Inc. serves as a bridge between basic science and preclinical drug discovery for Novartis’ global research organization. Its focus areas include oncology, autoimmunity, cardiovascular disease, diabetes, musculoskeletal disorders, and infectious disease. The company was founded in 1999 and is headquartered in San Diego, CA. | Corporate Officer/Principal | 31/12/2009 |
Forward Ventures Services LLC
Forward Ventures Services LLC Investment ManagersFinance Forward Ventures Services LLC (Forward Ventures ) is a venture capital firm founded in 1990 by Standish M. Fleming and Ivor Royston. The firm is headquartered in San Diego, California. | Analista de Capital Privado | 31/12/2008 |
Phenomix Corp.
Phenomix Corp. Pharmaceuticals: MajorHealth Technology Phenomix Corp. is a biopharmaceutical company focused on the discovery, development and commercialization of novel small-molecule product candidates directed toward clinically validated targets in significant therapeutic markets. It's internally discovered product candidates are designed to have improved efficacy, safety or convenience relative to existing therapies and other product candidates in clinical development. Its lead product candidate, dutogliptin tartrate, is a dipeptidyl peptidase-4, or DPP-4, inhibitor that it is developing as an oral, once-daily treatment for Type 2 diabetes. Its Phase 2b clinical trial of dutogliptin demonstrated statistically significant reductions in HbA1c when administered in combination with existing drugs for the treatment of Type 2 diabetes. The company commenced its Phase 3 clinical program in the third quarter of 2008. Its second product candidate, PHX1766, is a protease inhibitor currently in Phase 1 of clinical development for the treatment of hepatitis C virus, or HCV, infection. The company intends to maximize the value of its product candidates through independent development, licensing and other partnership opportunities. These may include co-development or co-marketing agreements, licensing agreements with pharmaceutical and biotechnology companies that possess established development and commercialization capabilities or direct commercialization by building its own sales and marketing force. | Corporate Officer/Principal | 30/09/2006 |
░░░░░░░░ ░░░░░░░░░░ ░░░░ | ░░░░░░░░░░ | - |
░░░░░ ░░░░░░░░░░░░░ ░░░░ | ░░░░░░░░░░░░░░░░ ░░ ░░ ░░░░░ | - |
Formación de Nancy Hong.
California Institute of Technology | Undergraduate Degree |
University of California, Berkeley | Doctorate Degree |
Experiencias
Funciones ocupadas
Relaciones
Relaciones de 1er grado
Empresas vinculadas al 1er grado
Hombre
Mujer
Administradores
Ejecutivos
Empresas relacionadas
Empresas cotizadas | 1 |
---|---|
XILIO THERAPEUTICS, INC. | Health Technology |
Empresas privadas | 11 |
---|---|
Forward Ventures Services LLC
Forward Ventures Services LLC Investment ManagersFinance Forward Ventures Services LLC (Forward Ventures ) is a venture capital firm founded in 1990 by Standish M. Fleming and Ivor Royston. The firm is headquartered in San Diego, California. | Finance |
Phenomix Corp.
Phenomix Corp. Pharmaceuticals: MajorHealth Technology Phenomix Corp. is a biopharmaceutical company focused on the discovery, development and commercialization of novel small-molecule product candidates directed toward clinically validated targets in significant therapeutic markets. It's internally discovered product candidates are designed to have improved efficacy, safety or convenience relative to existing therapies and other product candidates in clinical development. Its lead product candidate, dutogliptin tartrate, is a dipeptidyl peptidase-4, or DPP-4, inhibitor that it is developing as an oral, once-daily treatment for Type 2 diabetes. Its Phase 2b clinical trial of dutogliptin demonstrated statistically significant reductions in HbA1c when administered in combination with existing drugs for the treatment of Type 2 diabetes. The company commenced its Phase 3 clinical program in the third quarter of 2008. Its second product candidate, PHX1766, is a protease inhibitor currently in Phase 1 of clinical development for the treatment of hepatitis C virus, or HCV, infection. The company intends to maximize the value of its product candidates through independent development, licensing and other partnership opportunities. These may include co-development or co-marketing agreements, licensing agreements with pharmaceutical and biotechnology companies that possess established development and commercialization capabilities or direct commercialization by building its own sales and marketing force. | Health Technology |
Novartis Institute for Functional Genomics, Inc.
Novartis Institute for Functional Genomics, Inc. Miscellaneous Commercial ServicesCommercial Services Novartis Institute For Functional Genomics, Inc. serves as a bridge between basic science and preclinical drug discovery for Novartis’ global research organization. Its focus areas include oncology, autoimmunity, cardiovascular disease, diabetes, musculoskeletal disorders, and infectious disease. The company was founded in 1999 and is headquartered in San Diego, CA. | Commercial Services |
BioMed Ventures
BioMed Ventures Investment ManagersFinance BioMed Ventures (BioMed Ventures) is a venture capital firm subsidiary of BioMed Realty founded in 2010. The firm is headquartered in San Diego, California. | Finance |
RiverVest Venture Management LLC
RiverVest Venture Management LLC Investment ManagersFinance RiverVest Venture Management LLC (RiverVest Venture Partners) is a venture capital firm founded in 2000 by Thomas Melzer, Craig Andrew and Jay Schmelter. The firm is headquartered in St. Louis, Missouri. | Finance |
Archmont Biopharma, Inc.
Archmont Biopharma, Inc. Pharmaceuticals: MajorHealth Technology Archmont Biopharma, Inc. develops bone-targeted gene therapy for patients. The company is based in St. Louis, MO. | Health Technology |
Sequre Dx, Inc.
Sequre Dx, Inc. Medical/Nursing ServicesHealth Services Sequre Dx, Inc. is a genomics intelligence company that focuses on advancing on-target gene editing and cell therapies from discovery to patient. The company is based in Waltham, MA. The company offers preclinical platforms for the biopharma industry, including diagnostic assays and bioinformatic analytics that solve preclinical off-target evaluation needs. Sequre Dx aims to make gene editing and cell therapies suitable for all patients who would benefit from these life-saving technologies. The CEO of the company is Ellen E. Sheets. | Health Services |
Biolinq, Inc.
Biolinq, Inc. Electronic Production EquipmentElectronic Technology Biolinq, Inc. develops skin-applied electronic sensors that analyze body fluids to provide health information. The company was founded by Jared Tangney and Josh Windmiller in 2012 and is headquartered in San Diego, CA. | Electronic Technology |
Xilio Therapeutics LLC
Xilio Therapeutics LLC Pharmaceuticals: MajorHealth Technology Part of Xilio Therapeutics, Inc., Xilio Therapeutics LLC develops cancer biopharmaceuticals. The company is based in Waltham, MA. The CEO of the company is René Russo. | Health Technology |
Bluejay Therapeutics, Inc.
Bluejay Therapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services Bluejay Therapeutics, Inc. is a clinical stage private biopharmaceutical company that is committed to developing effective treatments and cures for viral and liver diseases. The company is based in San Mateo, CA, and was founded by Keting Chu, who has been the CEO since incorporation. The company's first target indication is chronic hepatitis b, which is a worldwide prevalent disease with an urgent unmet medical need. Bluejay is advancing two innovative approaches with the potential for a high rate of functional cure: fully human igg1 anti-hbs monoclonal antibodies and first-in-class hbsag oral small molecule inhibitors. The company believes that by reducing hepatitis b surface antigen and restoring adaptive immunity, a functional cure could be achieved for patients. | Commercial Services |
Scout Bio, Inc.
Scout Bio, Inc. Pharmaceuticals: MajorHealth Technology Scout Bio, Inc. operates as a biotechnology company that focuses on the innovation of pet medicine by delivering a pipeline of one-time therapeutics for major chronic pet health conditions. It also specializes in gene therapy, veterinary product development and biotechnology investment. The company was founded by James M. Wilson in 2016 and is headquartered in Philadelphia, PA. | Health Technology |
- Bolsa de valores
- Insiders
- Nancy Hong